Report: Sandoz fights to bring first biosimilar to U.S.
SAN FRANCISCO — Sandoz argued before the U.S Court of Appeals for the Federal Circuit Wednesday in an effort to lift a preliminary injunction barring the sale of its Zarxio biosimilar medicine, Reuters reported.
Amgen, the maker of Neupogen, sued to have Zarxio barred from the market this past fall for patent infringement.
According to Reuters, if the injunction were to be lifted, Zarxio would become the first biosimilar sold in the United States.
RxEOB appoints new tech VP
RICHMOND, Va. — Roopesh Kumar has been appointed the new VP, information technology at RxEOB, which develops and implements pharmacy benefit applications. In his position, Kumar will work to improve the company’s member engagement programs by focusing on advancements in health care technology.
“I’m looking forward to the opportunity to work closely with the experienced team at RxEOB to ensure deliverables are not only met, but exceeded,” Kumar said. “By using my experience in the IT field to improve processes and grow this department, we are able to further position RxEOB as the industry leader in providing proprietary, member-facing pharmacy benefit applications, medication pricing and messaging applications for use by our customer’s member and patient populations.”
Kumar was previously the lead on GE Healthcare’s tech team and has more than 15 years of IT experience at companies like Xerox and Fiserv.
“Roopesh is one-of-a-kind when it comes to his technical knowledge, possessing a superb understanding of web-based software design and development,” RxEOB CEO Robert Oscar said. “His extensive technical and managerial experience is a great asset to RxEOB as we continue to strive to provide the best member engagement applications available in the health care industry.”
Protein Sciences gains extensive patent protection for Flublok vaccine
MERIDEN, Conn. — Protein Sciences announced Wednesday that in a rare move, the Food and Drug Administration is granting exclusivity to Flublok for a period of 12 years. The U.S. FDA determination of regulatory exclusivity means that no product similar to Flublok can be approved by FDA before Jan. 16, 2025.
"We are delighted that the FDA recognizes Flublok as a singular innovation in the prevention of an important and often deadly disease caused by the influenza virus," said Manon Cox, president and CEO of Protein Sciences Corporation.
Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing.
According to the company, Flublok contains three times more antigen than traditional flu vaccines.
Loading Post Please Wait...